Congressional Research Service Reports - 537 Matching Results

Search Results

Tobacco Control: Enforcement and Effectiveness of Federal and State Youth Access Laws
No Description Available.
Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship
Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an understanding of the rationale for government support of R&D and subsequent efforts to facilitate private sector commercialization of new technologies generated from such work. Concerns surrounding innovation in pharmaceuticals and biotechnology are discussed within the broader context of the federal role in facilitating technological progress.
Summary and Comparison of the Major Agricultural Provisions of the Tobacco Settlement Policy Proposals
No Description Available.
The Proposed Tobacco Settlement: Who Pays for the Health Costs of Smoking?
No Description Available.
The Tobacco Settlement: An Overview
No Description Available.
The Proposed Tobacco Settlement: Effects on Prices, Smoking Behavior, and Income Distribution
No Description Available.
Compensating Farmers for the Tobacco Settlement
The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
The Tobacco Settlement: Issues
No Description Available.
Tobacco Master Settlement Agreement (1998): Overview, Implementation by States, and Congressional Issues
No Description Available.
Tobacco Advertising: Whether the FDA's Restrictions Violate Freedom of Speech
No Description Available.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Prescription Drug User Fee Act of 1992: Effects on Bringing New Drugs to Market
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches
The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practice of differential pricing. Finally, this report discusses various policy approaches aimed at assisting the elderly to purchase prescription drugs.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Importing Prescription Drugs
No Description Available.
Importing Prescription Drugs
No Description Available.
Prescription Drug Importation and Internet Sales: A Legal Overview
No Description Available.
Importing Prescription Drugs: Objectives, Options, and Outlook
No Description Available.
Prescription Drugs: Importation for Personal Use
No Description Available.
Ecstasy: Actions of the 107th Congress to Control MDMA
Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
Ecstasy: Actions of the 107th Congress to Control MDMA
Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
Ecstasy: Actions of the 107th Congress to Control MDMA
Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
Ecstasy: Legislative Proposals in the 107th Congress to Control MDMA
Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
Legal Issues Related to Prescription Drug Sales on the Internet
No Description Available.
Abortion Services and Military Medical Facilities
The purpose of this report is to describe and discuss the provisions for providing abortion services to military personnel, their dependents and other military health care beneficiaries at military medical facilities. The report describes the history of these provisions, with particular emphasis on legislative actions. Finally, this report discusses a number of proposals to modify the Clinton Administration provisions, as well as recently enacted legislation.
Abortion Services and Military Medical Facilities
The purpose of this report is to describe and discuss the provisions for providing abortion services to military personnel, their dependents and other military health care beneficiaries at military medical facilities. The report describes the history of these provisions, with particular emphasis on legislative actions. Finally, this report discusses a number of proposals to modify the Clinton Administration provisions, as well as recently enacted legislation.
Military Medical Care Services: Questions and Answers
No Description Available.
Military Medical Care Services: Questions and Answers
No Description Available.
Military Medical Care Services: Questions and Answers
No Description Available.
Military Medical Care Services: Questions and Answers
No Description Available.